Clusters of Cardiovascular Risk Factors and Their Impact on the 20-Year Cardiovascular Risk in a General Population.
Journal
The Journal of cardiovascular nursing
ISSN: 1550-5049
Titre abrégé: J Cardiovasc Nurs
Pays: United States
ID NLM: 8703516
Informations de publication
Date de publication:
Historique:
pubmed:
7
1
2020
medline:
31
8
2021
entrez:
7
1
2020
Statut:
ppublish
Résumé
Clustering of cardiovascular risk factors (CVRFs) is extraordinarily common and is associated with an increased risk of cardiovascular disease (CVD). However, the particular impact of the sum of CVRFs on cardiovascular morbidity and mortality has not been sufficiently explored in Europe. The aim of this study was to analyze the differences in survival-free probability of CVD in relation to the number of CVRFs in a Spanish population. A prospective cohort study was conducted from 1992 to 2016 in a Spanish population that included 1144 subjects with no history of CVD (mean age, 46.7 years) drawn from the general population. We calculated the number of CVRFs for each subject (male sex, smoking, diabetes, hypertension, dyslipidemia, obesity, and left ventricular hypertrophy). Cardiovascular morbidity and mortality records were collected, and survival analysis was applied (competing risk models). There were 196 cardiovascular events (17.1%). The differences in total survival-free probability of cardiovascular morbidity and mortality of the different values of the sum of CVRFs were significant, increasing the risk of CVD (hazard ratio, 1.30; 95% confidence interval, 1.13-1.50) per each additional risk factor. Differences in survival-free probability of CVD in relation to the number of CVRFs present were statistically significant. Further studies are needed to corroborate our results.
Sections du résumé
BACKGROUND
Clustering of cardiovascular risk factors (CVRFs) is extraordinarily common and is associated with an increased risk of cardiovascular disease (CVD). However, the particular impact of the sum of CVRFs on cardiovascular morbidity and mortality has not been sufficiently explored in Europe.
OBJECTIVE
The aim of this study was to analyze the differences in survival-free probability of CVD in relation to the number of CVRFs in a Spanish population.
METHODS
A prospective cohort study was conducted from 1992 to 2016 in a Spanish population that included 1144 subjects with no history of CVD (mean age, 46.7 years) drawn from the general population. We calculated the number of CVRFs for each subject (male sex, smoking, diabetes, hypertension, dyslipidemia, obesity, and left ventricular hypertrophy). Cardiovascular morbidity and mortality records were collected, and survival analysis was applied (competing risk models).
RESULTS
There were 196 cardiovascular events (17.1%). The differences in total survival-free probability of cardiovascular morbidity and mortality of the different values of the sum of CVRFs were significant, increasing the risk of CVD (hazard ratio, 1.30; 95% confidence interval, 1.13-1.50) per each additional risk factor.
CONCLUSION
Differences in survival-free probability of CVD in relation to the number of CVRFs present were statistically significant. Further studies are needed to corroborate our results.
Identifiants
pubmed: 31904694
doi: 10.1097/JCN.0000000000000637
pii: 00005082-202003000-00014
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
210-216Références
GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210.
GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1345–1422.
Yusuf S, Hawken S, Ounpuu S, et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952.
O'Donnell MJ, Chin SL, Rangarajan S, et al., INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388:761–775.
Institute for Health Metrics and Evaluation. GBD Compare. https://vizhub.healthdata.org/gbd-compare/. Updated 2018. Accessed March 2018.
Wang X, Bots ML, Yang F, et al. A comparison of the prevalence and clustering of major cardiovascular risk factors in the Netherlands and China. Eur J Prev Cardiol. 2016;23:1766–1773.
Yusuf HR, Giles WH, Croft JB, Anda RF, Casper ML. Impact of multiple risk factor profiles on determining cardiovascular disease risk. Prev Med. 1998;27:1–9.
Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633–644.
Grau M, Elosua R, Cabrera de León A, et al. Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study. Rev Esp Cardiol. 2011;64:295–304.
Cardiovascular disease in Europe 2016: an epidemiological update. Eur Heart J. 2016;37:3182–3183.
Peters SAE, Wang X, Lam TH, et al., Asia Pacific Cohort Studies Collaboration. Clustering of risk factors and the risk of incident cardiovascular disease in Asian and Caucasian populations: results from the Asia Pacific Cohort Studies Collaboration. BMJ Open. 2018;8:e019335.
Hirakawa Y, Lam TH, Welborn T, et al., Asia Pacific Cohort Studies Collaboration. The impact of body mass index on the associations of lipids with the risk of coronary heart disease in the Asia Pacific region. Prev Med Rep. 2015;3:79–82.
Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation. 2005;112:3384–3390.
Nakamura K, Barzi F, Huxley R, et al., Asia Pacific Cohort Studies Collaboration. Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases? Heart. 2009;95:909–916.
Tsukinoki R, Murakami Y, Huxley R, et al., Asia Pacific Cohort Studies Collaboration. Does body mass index impact on the relationship between systolic blood pressure and cardiovascular disease?: meta-analysis of 419 488 individuals from the Asia pacific cohort studies collaboration. Stroke. 2012;43:1478–1483.
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Rev Esp Cardiol (Engl Ed). 2016;69:939.
Palazón-Bru A, Carbayo-Herencia JA, Simarro-Rueda M, et al., GEVA (Group of Vascular Diseases From Albacete). Comparison between non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol to estimate cardiovascular risk using a multivariate model. J Cardiovasc Nurs. 2018;33:E17–E23.
de Burgos-Lunar C, Salinero-Fort MA, Cárdenas-Valladolid J, et al. Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care. BMC Med Res Methodol. 2011;11:146.
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446.
American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
SEEDO'2000 consensus for the evaluation of overweight and obesity and the establishment of criteria for therapeutic intervention. Sociedad Española para el Estudio de la Obesidad. Med Clin (Barc). 2000;115:587–597.
Wolbers M, Blanche P, Koller MT, Witteman JC, Gerds TA. Concordance for prognostic models with competing risks. Biostatistics. 2014;15:526–539.
Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–362.
Artigao-Ródenas LM, Carbayo-Herencia JA, Palazón-Bru A, et al. Construction and validation of a 14-year cardiovascular risk score for use in the general population: the Puras-GEVA Chart. Medicine (Baltimore). 2015;94:e1980.
Conroy RM, Pyörälä K, Fitzgerald AP, et al., SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.
Kotseva K, De Backer G, De Bacquer D, et al., EUROASPIRE Investigators. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824–835. doi:10.1177/2047487318825350.
doi: 10.1177/2047487318825350
Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaard M, CRUCIAL Trial Investigators. Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis. Vasc Health Risk Manag. 2014;10:145–156.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.